Back to News
Market Impact: 0.35
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Source: PR Newswire
Corporate EarningsCompany FundamentalsCurrency & FX
Revenue was RMB 11.8B, up 18.4% YoY (23.4% YoY in USD), while IFRS gross margin rose 350 bps to 46.2% and adjusted gross margin increased 280 bps to 48.4%. Despite foreign-exchange headwinds, EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY, indicating improving profitability but slower bottom-line growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- The hawk Fed Chair who broke the bond market?
- JPMorgan Chase, Goldman and other big banks report earnings this week. What to expect
- BridgeBio presents encaleret trial data, doses first patient
- Big Banks Face Test as Earnings Season Begins
- This Chinese memory chip maker has global potential and is poised to outperform
- Trump’s tariffs forced U.S. factories to close down or lay off workers, and longtime GOP voters are revolting—’It was like taking a knife to the back’